ReviewPolymers2025
Chitosan as a Plurivalent Biopolymer in Nanodelivery Systems.
Review in Polymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Alpha‑lipoic acid-loaded chitosan nanoparticles ameliorate streptozotocin‑induced diabetic liver injury via Nrf2/HO‑1 activation and TLR4/NF‑κB and JAK2/STAT1 inhibition.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Amylopectin-Polymers · 2026Article
- Chitosan nanoparticles for mucosal and needle-free vaccination.NPJ vaccines · 2026Review
- Natural Polymers in Tissue Engineering and Regeneration: Material-Cell Mechanotransduction, Biofabrication Strategies, and Clinical Translation.Biomedicines · 2026Review
- Research trends and hotspots of nanomaterials in Alzheimer's disease: bibliometric analysis.Discover nano · 2026Review
- The concurrent silencing of Tim-3 and STAT-3 promotes tumor regression both in vitro and in ovo.BMC cancer · 2025Article
- Chitosan Nanoparticle-Based Drug Delivery Systems: Advances, Challenges, and Future Perspectives.Polymers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Background: This review study will delve into the potential of chitosan nanoparticles (NPs) as adaptable carriers for targeted drug delivery in different therapeutic areas. Chitosan is a biopolymer derived from chitin that has attracted interest in drug delivery applications because of its high biocompatibility and biodegradability. (2) Methods: A comprehensive literature review was conducted by following a careful systematized protocol for searching databases like PubMed, Google Scholar and ScienceDirect. (3) Results: Chitosan NPs are good drug delivery vehicles, notably for cancer. Studies reveal that doxorubicin-loaded chitosan NPs dramatically enhance toxicity to tumor cells compared to free medicines, yielding tumor suppression rates of up to 60%. Researchers found that chemotherapeutics had an 85% encapsulation efficiency (EE), lowering systemic toxicity. Magnetic and pH-responsive chitosan NPs boost drug accumulation by 63% and apoptosis by 54%. Chitosan also boosts medication retention in the lungs by 2.3×, per pulmonary delivery trials. Chitosan NPs also boost ocular medication bioavailability by 3× and improve nasal absorption by 30%, crossing the blood-brain barrier. For bone regeneration, chitosan scaffolds enhance bone mineral density by 46%, facilitating osteogenesis and healing. (4) Conclusions: NPs made of chitosan provide a solid foundation for improving drug delivery systems; yet there are still issues with material variability, scalability, and meeting regulatory requirements that need fixing. Research into combination treatments, ways to increase their specificity, and ways to optimize these NPs offers promising prospects for the creation of novel therapeutic approaches with the potential to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.